<DOC>
	<DOCNO>NCT00016042</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Biological therapy use different way stimulate immune system stop cancer cell grow . Combining chemotherapy biological therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness fluorouracil combine biological therapy treat patient metastatic kidney colorectal cancer .</brief_summary>
	<brief_title>Fluorouracil Biological Therapy Treating Patients With Metastatic Kidney Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety fluorouracil interleukin-12-primed activated T cell ( 12ATC ) sargramostim ( GM-CSF ) interferon alfa patient metastatic renal cell cancer colorectal cancer . II . Determine maximum tolerate dose 12ATC patient population . III . Determine clinical response patient treat regimen . OUTLINE : This dose-escalation study interleukin-12-primed activate T cell ( 12ATC ) . Patients receive sargramostim ( GM-CSF ) subcutaneously ( SC ) day 1-5 undergo leukopheresis day 6 obtain peripheral blood mononuclear cell ( PBMC ) . Patients treat dose level 3 also undergo leukopheresis day 7 . The PBMC treat monoclonal antibody anti-CD3 , interleukin-12 interleukin-2 form 12ATC . Patients receive chemo/immunotherapy comprise fluorouracil IV continuously 24 hour day 13 GM-CSF interferon alfa SC day 17 , 19 , 21 , 24 , 26 , 28 . Patients receive 12ATC IV 15-30 minute day 31 , 34 , 38 , 41 , 45 , 48 interferon alfa SC day 35 , 42 , 49 . Cohorts 3-6 patient receive escalate dos 12ATC maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . Patients follow 2 week , every 3 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 9-18 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell carcinoma colorectal carcinoma Failed prior standard salvage therapy OR Ineligible standard therapy due concurrent illness OR Declined standard therapy Bidimensionally measurable disease ( CT scan MRI ) outside prior irradiation port unless documented disease progression radiotherapy No untreated unstable treat brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Total granulocyte count least 2,000/mm3 Hemoglobin least 10 g/dL No coagulation disorder thrombophlebitis Hepatic : Bilirubin great 2.5 mg/dL SGOT/SGPT le 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN PT/PTT great 1.5 time control Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No active ischemia and/or ejection fraction le 45 % No unstable angina No uncontrolled congestive heart failure Pulmonary : FEV1 FVC great 65 % predict No uncontrolled pulmonary embolism Other : No prior malignancy within past 5 year except resect basal cell carcinoma carcinoma situ cervix No active systemic infection No autoimmune disease No uncontrolled thyroid abnormalities No major medical illness HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : More 1 month since prior biologic therapy immunotherapy Chemotherapy : More 1 month since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : At least 4 week since prior steroid therapy steroidcontaining compound At least 2 week since prior topical inhale steroid No concurrent steroids Radiotherapy : More 1 month since prior radiotherapy , interstitial brachytherapy , radiosurgery Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>